The overall goal of Core D is to provide the Program Project with a preclinical pharmacology program for the protease inhibitors that are identified in Project 1 and Core B, and tested in Projects 2 and 3. This will be accomplished by defining the disposition processes responsible for elimination of the protease inhibitors, by characterizing the pharmacokinetics of protease inhibitors in animal models, and by developing pharmacokinetic/pharmacodynamic correlations with respect to both measures of efficacy and toxicity.
Specific aims i n Core D are: 1) determine the processes responsible for the inactivation of protease inhibitors identified in Core B and the novel inhibitors designed and synthesized in Project 1; test the hypothesis that small molecule protease inhibitors are likely to be substrates for CYP3A and p-glycoprotein; 2) quantitate the presence (or confirm the absence) of potential """"""""inactivators"""""""" of the developed protease inhibitors within the in vitro cell biological assays and animal tumor models used in Core C and Projects 2 and 3; 3) test promising protease inhibitors (on the basis of Project 2 studies) in preclinical animal models using pharmacokinetic and pharmacodynamic methods; 4) Utilizing sparse data sampling analysis techniques, define the pharmacokinetics of the promising protease inhibitors in animal models. 5) Use population analysis methods with concentration-efficacy/toxicity measurements to develop pharmacokinetic/pharmacodynamic models for the promising protease inhibitors (using measurements obtained in Project 2 and those from this Core). In this way Core D serves our overall Program Project application by evaluating and optimizing the in vivo preclinical studies of Projects 2 and 3, and Core C required to assess the efficacy and/or toxicity of the protease inhibitors identified in Core B and/or designed and synthesized in Project 1.
| Sathler, Plinio Cunha; Lourenco, Andre Luiz; Miceli, Leonardo Alves et al. (2014) Structural model of haptoglobin and its complex with the anticoagulant ecotin variants: structure-activity relationship study and analysis of interactions. J Enzyme Inhib Med Chem 29:256-62 |
| LeBeau, Aaron M; Duriseti, Sai; Murphy, Stephanie T et al. (2013) Targeting uPAR with antagonistic recombinant human antibodies in aggressive breast cancer. Cancer Res 73:2070-81 |
| Darragh, Molly R; Schneider, Eric L; Lou, Jianlong et al. (2010) Tumor detection by imaging proteolytic activity. Cancer Res 70:1505-12 |
| Sounni, Nor E; Dehne, Kerstin; van Kempen, Leon et al. (2010) Stromal regulation of vessel stability by MMP14 and TGFbeta. Dis Model Mech 3:317-32 |
| Littlepage, Laurie E; Sternlicht, Mark D; Rougier, Nathalie et al. (2010) Matrix metalloproteinases contribute distinct roles in neuroendocrine prostate carcinogenesis, metastasis, and angiogenesis progression. Cancer Res 70:2224-34 |
| Kessenbrock, Kai; Plaks, Vicki; Werb, Zena (2010) Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 141:52-67 |
| Lederle, Wiltrud; Hartenstein, Bettina; Meides, Alice et al. (2010) MMP13 as a stromal mediator in controlling persistent angiogenesis in skin carcinoma. Carcinogenesis 31:1175-84 |
| Barkan, David T; Hostetter, Daniel R; Mahrus, Sami et al. (2010) Prediction of protease substrates using sequence and structure features. Bioinformatics 26:1714-22 |
| Sun, Cheng; Su, Kai-Hung; Valentine, Jason et al. (2010) Time-resolved single-step protease activity quantification using nanoplasmonic resonator sensors. ACS Nano 4:978-84 |
| Andreu, Pauline; Johansson, Magnus; Affara, Nesrine I et al. (2010) FcRgamma activation regulates inflammation-associated squamous carcinogenesis. Cancer Cell 17:121-34 |
Showing the most recent 10 out of 134 publications
